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Abstract
Our study aims to study the therapeutic effects of a novel Bcl-2 inhibitor, ABT-263, on hepatocellular carcinoma (HCC) and
to provide primary preclinical data for future clinical trial with ABT-263. In this study we showed that Bcl-xL and survivin
were up-regulated in HCC cell lines and human liver cancer tissues. Clinic used ABT-263 single treatment had no apoptotic
effects on HCC cells whereas higher doses of ABT-263 did. Interestingly, the combination treatment of ABT-263 with survivin
inhibitor YM-155 could result in significant apoptosis in HCC cells. Survivin inhibition through gene silencing significantly
enhanced ABT-263 to induce apoptosis in HCC cells. We found that low dose of ABT-263 single treatment resulted in ERK
activation and survivin up-regulation, which might be involved in the resistance of HCC cells to ABT-263 since blockade of
ERK activation sensitized ABT-263-induced apoptosis. Importantly, ABT-263 and YM-155 combination treatment had no
apoptotic effects on normal human hepatocytes. Taken together, these data suggest the combination treatment of Bcl-2
inhibitor and survivin inhibition may have a great potential for liver cancer therapy.
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Introduction
Currently, there are no effective therapies for liver cancer other
than surgical resection or liver transplantation in the early stages of
tumor development. However, such treatments only apply to a
small percentage of patients while the majorities die within 12
months of diagnosis. Therefore, new therapeutic strategies are
urgently needed.
Overwhelming evidence are showing that up-regulation of the
anti-apoptotic proteins of the Bcl-2 family is one of the
mechanisms employed by cancer cells to evade apoptosis [1–3].
Small molecule inhibitors have now been designed to combat this
ability of cancer cells. Of all, ABT-263 is a novel second
generation orally bio-available Bcl-2 homology domain 3 (BH3)-
mimetic that inhibits the anti-apoptotic Bcl-2 family proteins (Bcl-
2, Bcl-xL, and Bcl-v) [4]. It has been shown to be effective in
inducing apoptosis and tumor regression in small cell lung cancer,
acute lymphoblastic leukemia, multiple myeloma and lymphoid
malignancies either as a single agent or in combination with other
agents [5–8]. However, the therapeutic effects of ABT-263 on liver
cancers are not known.
Meanwhile, survivin, another anti-apoptotic protein is known to
be over-expressed in most cancers including liver cancers [9,10].
Consequently, it has been becoming a very attractive target in
cancer therapy. YM-155, a novel small imidazolium-based agent
was shown to have specific activity against survivin with no
associated systemic toxicity [11,12]. YM-155 has demonstrated a
safe profile and anti-tumor activity in a phase I trial that included
patients with non-small cell lung cancer, esophageal cancer,
prostate cancer cells and non-Hodgkin lymphoma [13–16].
Similar to ABT-263, the anti-tumor effects of YM-155 on HCC
remain unknown.
In the present study, we examined the apoptotic effects of ABT-
263 treatment on HCC cells. We provided evidence for the first
time to show that low doses of ABT-263 treatment could not
induce apoptosis in HCC cells. However, pre-incubation with
survivin inhibitor YM-155 or survivin gene silencing by siRNA
sensitized HCC cells to ABT-263-induced apoptosis. ERK
activation and survivin up-regulation may contribute to the
insensitivity of HCC cells to ABT-263. ABT-263 and YM-155
combination treatment had no apoptotic toxicity to normal
human hepatocytes. Collectively, these findings provide a novel
framework for understanding the mechanism of action of ABT-
263 and possibly the rational integration of two agents into anti-
HCC regimens.
Materials and Methods
Cell culture and reagents
Ethics statement: with the approval by the University of Florida
Gainesville Health Science Center Institutional Review Board
(IRB-01) and with informed written consent, liver cancer tissues
and non-tumor liver tissues from same patients respectively were
collected and analyzed. The LH86 human HCC cell line was
established in our laboratory as previously described [17]. Huh7
cells were obtained from the American Type Culture Collection
(ATCC) (Manassas, VA). Human hepatocellular carcinoma Huh7
and LH86 cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) with 10% fetal bovine serum (Sigma, St. Louis,
MO) and antibiotics (100 U/ml penicillin and 100 mg/ml
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hepatocytes were obtained from CellzDirect Inc (Austin, TX). The
cells were cultured in DMEM/F12 (1:1) culture medium. The
human normal hepatocytes used were at least 90% viable before
treatment. Cells in culture were treated with ABT-263 alone or
YM-155 alone (both dissolved in DMSO) or a combination of
both. Untreated cells were always used as controls and exposed to
equal volume of DMSO as for treated cells. ABT-263 and YM-
155 were purchased from Selleck Chemical (Houston, TX);
Hoechst 33258, anti-b-actin antibody, and crystal violet were
obtained from Sigma (St Loius, MO); PD98059 were from
Calbiochem (Gibbstown, NJ); anti-caspase 9, anti-caspase 3, anti-
Bcl-xL, anti-Mcl-1, anti-survivin, anti-Bad, anti-Bax, anti-Bak,
anti-ERK, and anti-p-ERK polyclonal primary antibodies were
obtained from Cell Signaling Technology (Beverly, MA).
Western blotting
Cells were grown in a monolayer in 6-well plates and treated
with drugs as mentioned above until 60%-70% confluent. Cells
were harvested, washed twice with 16PBS and resuspended in
lysis buffer containing Nonidet P-40 (10 mM HEPES, pH 7.4,
2 mM EGTA, 0.5% Nonidet P-40, 1 mM NaF, 1 mM NaVO4,
1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 50 mg/
ml trypsin inhibitor, 10 mg/ml aprotinin, and leupeptin) and
incubated on ice for 30 min. After centrifugation at 12,0006g at
4uC for 15 min, the supernatant was transferred to a new tube and
the protein concentration was determined. Equivalent samples
(20 mg of protein) were subjected to SDS-PAGE on 12% gels. The
proteins were transferred to nitrocellulose membranes and probed
with the specific primary antibodies. The Immunoreactive
proteins were visualized by incubating in HRP-conjugated
secondary antibodies. Chemiluminescence was detected by
incubating in an equal-parts mixture of the SuperSignal West
Pico stable peroxide solution and luminol/enhancer solution
(Pierce, Rockford, IL) and subsequently using an image processing
machine. The molecular sizes of the proteins detected were
determined by comparison with prestained protein markers, Bio-
Rad (Hercules, CA).
Hoechst staining
Cells were seeded onto coverslips in 6-well plates in 10% FBS-
containing medium and then treated with ABT-263 or YM-155 as
mentioned above. After removal of culture medium cells were
exposed to staining solution containing Hoechst 33258(1 mg/ml) at
37uC for 10–30 min. Cells with chromatin condensation were
visualized and photographed using a digital fluorescence micro-
scope (Olympus) 30 min after addition of the staining solution.
Chromatin condensation is the most characteristic feature of
apoptosis. Apoptotic cell death ratio was assessed by counting the
number of apoptotic cells with condensed nuclei in six to eight
randomly selected areas.
Small interfering RNA (siRNA) transfection
Cells were grown in a monolayer in 6-well plates until 60%–
70% confluent. SiRNA transfection was performed according to
the manufacturer’s instructions. Briefly, cells were plated at a
density of 0.5610
6 cells/well in 6-well plates. Cells were
transfected with 100 nM siRNA duplex mixture (Cell signaling
Biotechnology, Beverly, MA) for 24 h in the presence of
lipofectamine RNAiMax (Invitrogen Inc., Carlsbad, CA). A non-
specific control siRNA (Cell signaling Biotechnology, Beverly, MA)
was also transfected at the same concentration as the negative
control.
Colony formation assay
Colony formation assay was performed as described previously
[18,19] with modification. Cells were seeded in 6-well plates at a
density of 1000 cells. Cells were untreated or treated with ABT-
263, YM-155, or combination of ABT-263 and YM-155 for 48 h.
After being rinsed with fresh medium, cells were allowed to grow
for 14 days to form colonies, which were then stained with crystal
violet (0.4 g/L; Sigma). Clonogenic assay was used to elucidate the
possible differences in long-term effects the combination on
human HCC cells.
Statistical analysis
Statistical analysis was performed using Student’s t test analysis,
with P values,0.05 considered significant.
Results
Bcl-xL is up-regulated in human HCC cell lines and liver
cancer tissues
To understand the roles of Bcl-2 family of proteins in HCC, liver
cancer tissues from more than 10 different patients and non-tumor
liver tissues from same patients respectively were collected and
analyzed for protein expression through Western blotting.As shown
in Figure 1A, compared with normal liver tissues, there was
consistentup-regulationofBcl-xLand survivinproteinexpressionin
three representative liver tumor tissues, whereas Mcl-1 was down-
regulated. Meanwhile, Bcl-xL, survivin and Mcl-1 protein expres-
sion wasexamined innormalhumanhepatocytes and two HCCcell
lines: LH86 and Huh7. Consistent with data from the human tissue
study, the two human liver cancer cell lines had increased
expression of Bcl-xL and survivin in comparison to the normal
primary hepatocytes. While Mcl-1 was down-regulated in both liver
tumor tissues and HCC cell lines (Figure 1B). These results suggest
that Bcl-2 family protein member Bcl-xL and survivin may be very
important for the metastasis or development of HCC.
HCC cells are resistant to low doses of ABT-263
Given the elevated expression of Bcl-xL in HCC cells, we
evaluated the therapeutic effects of ABT-263, a potent Bcl-2 family
inhibitor that has been used for treatment of other cancers such as
small-cell lung cancer and lymphoid malignancies clinically. A
previous report has shown that ABT-263 peak and efficacy plasma
concentrations were 7.7 mM [4]. Thus, in our study, cells were
untreated or treated with different doses of ABT-263 (0–20 mM)
for 24 h. Apoptosis assays were performed by Hoechst 33258
staining for nuclear morphology and Western blotting for caspases
activation. As shown in Figure 2A and 2B, and 2C, the higher dose
of ABT-263 (10–20 mM) treatment for 24 h induced significant
DNA fragmentation and caspase 9 or 3 cleavage activation in
HCC cells, whereas lower concentrations of ABT-263 (0–2.5 mM)
had no apoptotic toxicity to HCC cells. These results suggest that
HCC cells are relatively resistant to low doses of ABT-263.
Survivin YM-155 sensitizes ABT-263-induced apoptosis in
HCC cells
Survivin has been reported to be highly expressed in liver cancer
cells, which contributes to the multi-drug resistance and tumor
recurrences [20–23]. In this study, we also observed that survivin
over-expressed in HCC. To find outthe mechanism underliningthe
relative resistance of HCC cells to low dose ABT-263, we examined
whether survivin is involved in the resistance of HCC cells to Bcl-2
inhibitor. Both LH86 and Huh7 cells were treated with ABT-263
(1 mM), YM-155 (1 mM), or pre-treated with YM-155 (1 mM) for
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3D, 3E and 3F, neither ABT-263(1 mM) nor YM-155(1 mM) single
treatment was able to induce apoptotic events in HCC cells.
Surprisingly, a combination treatment of ABT-263 (1 mM) with
YM-155 (1 mM) induced dramatic apoptosis within 6 h. Additional
experiments were done to determine the anti-tumor activities of
combinationof ABT-263 and YM-155 inhibition when analyzed by
in vitro colony formation assays. As shown in Figure 3G and 3F,
median dose of ABT-263 and YM-155 combination treatment
significantly reduced HCC cell proliferation. These results suggest
that survivin inhibitor YM-155 can sensitize ABT-263 to induce
apoptosis in HCC cells.
Survivin down-regulation sensitizes ABT-263 to induce
apoptosis in HCC cells
YM-155 has been reported be able to inhibit survivin expression
at transcription level [24]. To confirm whether the apoptosis
enhancing effects observed in Figure 3 are mediated by survivin
Figure 1. Bcl-xL is up-regulated in liver tumor tissues and HCC cells. A. Lysates from normal liver tissues and liver tumor tissues of different
patients were prepared and subjected to Western blotting. Bcl-xL, Mcl-1, and survivin expressions were detected with specific antibodies. b-actin
protein levels were assessed as an equal protein loading control (P1, P2, and P3: patient number). B. Cell lysates from human normal primary
hepatocytes and HCC cells LH86 and Huh7 were prepared and Western blotting was performed to detect Bcl-xL, Mcl-1, and survivin expression with
specific antibodies. b-actin protein levels were assessed as an equal protein loading control.
doi:10.1371/journal.pone.0021980.g001
Figure 2. HCC cells are resistant to low doses of ABT-263. A. LH86 and B. Huh7 cells were treated with ABT-263 (0–20 mM) for up to 24 h.
Apoptosis was measured through Hoechst staining to show apoptotic cells with condensed nuclei as described in ‘materials and methods’.
(representative apoptotic cells were marked with white arrows in ABT-263 treatment panel). C. HCC cells were treated with increasing doses of ABT-
263 as indicated for up to 24 h. Then cells were harvested and cell lysates were prepared and subjected to Western blotting. Caspase activation was
assessed through detecting the cleaved bands of caspase 9 and caspase 3. b-actin protein levels were used as an equal protein loading control.
doi:10.1371/journal.pone.0021980.g002
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HCC cells treated with ABT-263 (1 mM), YM-155 (1 mM), or the
combination of YM-155 (1 mM) and ABT-263 (1 mM). As shown
in Figure 4A, the combination treatment of HCC cells with ABT-
263 (1 mM) and YM-155 (1 mM) for up to 6 h has no effects on the
expressions of either anti-apoptotic protein Bcl-xL or pro-
apoptotic proteins including Bad, Bak, and Bax. However, as
expected, the presence of YM-155 significantly decreased survivin
protein expression (Figure 4B, left third lane). Co-treatment of cells
with ABT-263 (1 mM) and YM-155 (1 mM) induced an even
greater decrease in survivin protein expression (Figure 4B, right
two lanes) than that of YM-155 itself did. However, we indeed
observed that ABT-263 single treatment for 3 h resulted in
survivin increase (Figure 4B). To further determine survivin
inhibition plays a critical role in sensitizing ABT-263 to induce
apoptosis in HCC cells, we down-regulated survivin expression in
HCC cells by siRNA duplexes targeted against human survivin
mRNA, and then examined the expression of survivin by Western
blotting (Figure 4C) and apoptotic events after ABT-263
treatments. The results demonstrated that ABT-263 induced
significant apoptosis in the survivin siRNA-transfected cells, but
not in siRNA Random-transfected (control) cells (Figure 4D, 4E,
and 4F). In addition, Mcl-1 was also down-regulated in cells
treated with YM-155 or the combination of ABT-263 and YM-
155 (Figure 4A). To explore whether Mcl-1 decrease contributed
to regulate YM-155 and ABT-263 co-treatment-induced apopto-
sis, we over-expressed Mcl-1 in HCC cells and found it could not
neutralize the combination triggered cytotoxicity (data not shown).
Figure 3. YM-155 sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 and B. Huh7 cells were untreated or treated with ABT-
263(1 mM), YM-155(1 mM) or combination of ABT-263(1 mM) and YM-155(1 mM) for up to 6 h. Then apoptotic cells were assessed as in Figure 2A and
2B (representative apoptotic cells were marked with white arrows). C. LH86 and D. Huh7 cells were untreated or treated with ABT-263(1 mM), YM-
155(1 mM) or combination of ABT-263(1 mM) and YM-155(1 mM) for 6 h. Cells with apoptotic nuclei were counted to determine cell death ratio
(*p,0.05, **p,0.05). E. LH86 cells and F. Huh7 cells were treated as indicated and cell lysates were prepared and subjected to Western blotting.
Apoptosis was evaluated through caspase 3 activation. b-actin was used as an equal protein loading control. G. LH86 cells grown in six-well plate
were untreated (control) or treated with different conditions as indicated for 48 h. After rinsed with fresh culture medium for 3 times, cells were
cultured for another two weeks. Cell colony formation assays were performed with crystal violet staining. H. colony number were counted to show
combination treatment with ABT-263 and YM-155 resulted in reduction of clonogenesis (#p,0.05).
doi:10.1371/journal.pone.0021980.g003
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plays a critical role for anti-cancer drug Bcl-2 inhibitor to induce
apoptosis in HCC cells.
Bcl-xL knocking down enhances survivin inhibitor
YM-155-induced apoptotic toxicity in HCC cells
To further determine survivin inhibition can reverse the
insensitivity of HCC cells in the presence of Bcl-xL activity
blockade. We down-regulated Bcl-xL protein expression in HCC
cells by siRNA duplexes targeted against human Bcl-xL mRNA
and then treated cells with YM-155. Knock down effects of Bcl-xL
were examined through Western blotting and apoptosis was
assessed through nuclear staining and caspase activation. As shown
in Figure 5A, compared with Random siRNA (negative control),
Bcl-xL protein expression was dramatically reduced. Moreover,
apoptotic data demonstrated that YM-155 induced significant
DNA fragmentation and caspase 3 cleavages in the Bcl-xL siRNA-
transfected cells, but not in siRNA control-transfected cells
(Figure 5B, 5C, and 5D). These results suggest that survivin
inhibition and Bcl-xL down-regulation is sufficient to induce
apoptosis in HCC cells.
ABT-263 induces ERK activation and survivin
up-regulation in HCC cells
Dys-regulation and activation of Raf-MEK-ERK-survivin has
been shown associated with anti-apoptotic capability of cancer
cells [25–28]. Consequently, in order to understand why lower
dose ABT-263 could not induce apoptosis of HCC cells, we
examined the effects of ABT-263 on ERK-survivin signal pathway
activation in HCC cells. On one hand, our data indicated that
Figure 4. Survivin down-regulation sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 cells were treated as indicated and cell
lysates were prepared for Western blotting. Pro-apoptotic proteins: Bax, Bad, and Bak and anti-apoptotic proteins Bcl-xL and Mcl-1 were assessed
with specific antibodies respectively. b-actin was detected and served as an equal protein loading control. B. LH86 cells were untreated or treated
with ABT-263 (1 mM), YM-155 (1 mM) or combination of ABT-263 (1 mM) and YM155 (1 mM) for up to 6 h as indicated. Then cells were harvested and
cell lysates were prepared for Western blotting. Anti-survivin and anti-Bcl-xL polyclonal antibodies were used to assess protein levels for survivin and
Bcl-xL respectively. b-actin was used as an equal protein loading control. The band intensities of survivin, Bcl-xL, and b-actin was qualified with Image
J software. C. LH86 cells were transiently transfected with synthesized random siRNA (control) or survivin specific siRNA duplexes, and 48 h post-
transfection, cells were subjected to Western blotting analysis with anti-survivin polyclonal antibody. b-actin was used as an equal protein loading
control. D. LH86 cells were transfected with synthesized random control siRNA or survivin specific siRNA, and 48 h post-transfection, cells were
untreated or treated with ABT-263 (1 mM) for 24 h and then subjected to Hoechst staining to show apoptotic cells with condensed nuclei
(representative apoptotic cells were marked with white arrows). E. LH86 cells were treated as in Figure 4D and apoptosis was measured as in
Figure 2A. Statistical analysis was performed for apoptosis ratio by counting the number of cells with apoptotic nuclei (*p,0.05). F. LH86 cells treated
as in Figure 4D were harvested and cell lysates were prepared and subjected to Western blotting. Apoptosis was determined through caspase 3
activation. b-actin was used as an equal protein loading control.
doi:10.1371/journal.pone.0021980.g004
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in the increase of phosphorylated ERK (p-ERK) but not ERK
(Figure 6A). On the other hand, as shown in Figure 6B or
Figure 4B, ABT-263 (1 mM) administration could result in
survivin expression increase. Thus, in an attempt to know if
ERK-survivin activation could protect cells against ABT-263
toxicity, cells were untreated or treated with ABT-263 (1 mM),
PD98059 (50 mM), or pre-treated with PD98059 (50 mM)
followed by ABT-263 (1 mM). As shown in Figure 6C and 6D,
blocking ERK activation with specific inhibitor PD98059
enhanced ABT-263-indcued apoptosis in HCC cells. To further
determine ERK anti-apoptotic effects on ABT-263 treated HCC
cells, we knocked down ERK expression through siRNA
mediated gene silencing (Figure 6E) and then administrated
ABT-263. Similar results revealed that ERK depletion sensitized
ABT-263-induced apoptosis (Figure 6F). These results suggest the
activation of ERK-survivin may render cells to be resistant to low
dose ABT-263-induced apoptosis.
ABT-263 has no apoptotic toxicity to normal human
hepatocytes
Finally, we asked the question whether ABT-263, YM-155, or
the combination treatment of ABT-263 and YM-155 is toxic to
normal human hepatocytes in vitro. As shown in Figure 7, ABT-
263, YM-155 single treatment, or the combination treatment of
ABT-263 and YM-155 had no apoptotic toxicity in normal human
hepatocytes, whereas, in positive control, the combination
treatment induced significant apoptosis in liver cancer cells. These
Figure 5. Bcl-xL down-regulation enhances YM-155-induced apoptotic toxicity in HCC cells. A. Huh7 cells were transiently transfected
with synthesized random siRNA (control) or Bcl-xL specific siRNA duplexes, and 48 h post-transfection, cells were subjected to Western blotting
analysis with anti-Bcl-xL polyclonal antibody. b-actin was used as an equal protein loading control. B. Huh7 cells were transfected with synthesized
random control siRNA or Bcl-xL specific siRNA, and 48 h post-transfection, cells were untreated or treated with YM-155 (1 mM) for 24 h and then
subjected to Hoechst staining to show apoptotic cells with condensed nuclei (representative apoptotic cells were marked with white arrows). C.
Huh7 cells were treated as in with YM-155 as indicated and apoptosis was measured as in Figure 2A. Statistical analysis was performed for apoptosis
ratio by counting the number of cells with apoptotic nuclei (*p,0.05). D. Huh7 cells treated were harvested and cell lyates were prepared and
subjected to Western blotting. Apoptosis was determined through caspase 3 activation. b-actin was used as an equal protein loading control.
doi:10.1371/journal.pone.0021980.g005
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inhibitors is safe to normal human liver cells.
Discussion
In the present study, we first provide evidence to show that
relative low doses of ABT-263 could not promote apoptosis in
human HCC cell lines. Significant apoptotic effects were observed
when ABT-263 was used along with YM-155. Survivin down-
regulation appears to be critical to sensitize ABT-263-induced
apoptosis in HCC cells. ERK activation and survivin up-
regulation induced by Low dose of ABT-263 may protect HCC
cells against apoptosis. This combination treatment of ABT-263
and YM-155 has no apoptotic toxicity to normal human
hepatocytes.
It is well known that Bcl-2 family members are anti-apoptotic
proteins and play critical roles in tumor genesis. Hence, it is
possible to induce apoptosis by targeting them with inhibitors such
as ABT-263. This strategy has been shown to be promising in
treatment of a number of cancers such as small cell lung cancer,
acute lymphoblastic leukemia, multiple myeloma, and lymphoid
malignancies [29–32]. However, it was unknown whether the use
Figure 6. ABT-263 induces activation of ERK and survivin up-regulation in HCC cells. A. LH86 cells were treated with different doses of
ABT-263 as indicated for 1 h. Cells were harvested and cell lysates were prepared for Western blotting. Phospho-ERK and ERK protein levels were
examined with specific antibodies. b-actin was assessed and served as an equal protein loading control. B, LH86 cells were untreated or treated with
ABT-263 (1 mM) for 1 h. Cells were harvested and cell lysates were prepared for Western blotting. Survivin expression level was examined with specific
antibodies. b-actin was assessed and served as an equal protein loading control. C. LH86 cells were not treated (control) or treated with ABT-
263(1 mM), ERK specific inhibitor PD98059 (50 mM), or pre-treated with PD98059 (50 mM) for 1 h followed by ABT-263 (1 mM) for 24 h. Apoptosis was
determined by Hoechst staining to show cells with apoptotic nuclei (representative apoptotic cells were labeled with white arrows; PD: PD98059). D.
LH86 cells were treated as in Figure 6C, apoptosis was assessed by nuclear staining and cells with apoptotic nuclei were counted as described in
‘materials and methods’ (*p,0.05). E. LH86 cells were untransfected or transiently transfected with synthesized random siRNA (control) or ERK
specific siRNA duplexes, and 48 h post-transfection, cells were subjected to Western blotting analysis with anti-ERK polyclonal antibody. b-actin was
used as an equal protein loading control. F. LH86 cells were transfected with synthesized random control siRNA or ERK specific siRNA, and 48 h post-
transfection, cells were untreated or treated with ABT-263 (1 mM) for 24 h and then subjected to Hoechst staining to show apoptotic cells with
condensed nuclei (representative apoptotic cells were marked with white arrows).
doi:10.1371/journal.pone.0021980.g006
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In our study, we firstly showed that Bcl-2 family protein Bcl-xL
is down-regulated in normal differentiated tissues or normal
human hepatocytes whereas is over-expressed in the majority of
malignancies. This is consistent with previous reports that Bcl-2
family proteins were elevated in liver tumor cells [33–37]. In
addition, unlike Bcl-xL, another Bcl-2 family anti-apoptotic
protein, Mcl-1, is decreased in tumor tissues and cell lines in
comparison with that in normal liver tissues and cells, of which
underlining reason and function remains further study; Bcl-2
protein expression is undetectable in either liver tumor or
normal samples, which is in agreement with reports that Bcl-2
is rarely expressed in liver tumor cells [38,39]. Secondly, we did
observe that very high doses of ABT-263 could induce
apoptosis in HCC cells. However, there are concerns about
the side effects of many chemotherapeutic agents including
those in clinical use. Thus, lower doses of ABT-263-induced
apoptosis were examined in HCC cells. Unfortunately, we
found that HCC cells were resistant to low concentration of
ABT-263. Our results are not in agreement with the studies,
which suggest that low doses of ABT-263 were sufficient to
induce apoptosis in cancer cells including small-cell lung cancer
and lymphoma cell lines [5,8]. This implies a possibility that in
some types of cancer cells, monotherapy via inhibition of anti-
apoptotic Bcl-2 family protein activity is not sufficient to trigger
apoptosis. Unfortunately, insof a r ,t h e r ei sn or e p o r tt os h o wt h e
reason why a number of cancer cells can not be killed by Bcl-2
inhibitor. In our study, with an attempt to understand the
insensitivity of HCC cells to low dose of ABT-263-induced
apoptosis, we found that another anti-apoptotic protein
survivin is up-regulated in liver tumor tissues or cell lines, but
rarely expressed in most normal tissues and undetectable in
normal liver cells, suggesting that it may facilitate cell resistant
to low doses of ABT-263 treatment. Our data showed that in
combination with the survivin inhibitor YM-155, very low dose
of ABT-263 induced significant apoptosis in HCC cells only in
6 h. Moreover, we found that knock down of Bcl-xL
significantly enhanced YM-155-induced apoptotic toxicity,
which further supported Bcl-xL inhibition-induced apoptosis
needs survivin inhibition. Our findings are in agreement with
studies that reported that YM-155 could enhance radiation
therapeutic agents-induced apoptosis in tumor cells [40].
Meanwhile, we found that the low dose of neither of these
agents was able to induce apoptotic cell death of HCC cells.
Third, we found that the sub-lethal dose of ABT-263 and YM-
155 that combined to effectively induce apoptotic cell death in
the HCC cells was not cytotoxic to human normal primary
hepatocytes. Collectively, these data are very interesting and
encouraging because they show that low doses of both ABT-263
and YM-155 may be used to effectively treat HCC with no
associated hepatotoxicity.
We are interested in determining the mechanisms of action
underlying the observed effects noted above. On one hand, our
experiments showed that ABT-263, YM-155, or ABT-263 and
YM-155 combination treatment had no effects on expression of
pro-apoptotic proteins such as Bad, Bax, and Bak or anti-
apoptotic Bcl-xL. However, YM-155 treatment could signifi-
cantly induce survivin protein decrease, but not that of anti-
apoptotic protein Bcl-xL, suggesting that YM-155 may sensitize
ABT-263-induced apoptosis via survivin down-regulation. On
the other hand, survivin knock-down through siRNA signifi-
cantly enhanced low dose of ABT-263 to induce apoptosis in
HCC cells, which further confirmed that survivin inactivation
indeed plays critical roles to determine cell sensitivity to Bcl-2
inhibitor toxicity. Meanwhile, we observed that Mcl-1 was also
decreased by either YM-155 single or combination treatment of
ABT-263 and YM-155, suggesting it may contribute to sensitize
ABT-263-induced apoptosis in HCC cells. However, further
experiments showed that over-expression of Mcl-1 could not
protect HCC cells against ABT-263 and YM-155 co-treatment-
induced apoptosis. Thus, Mcl-1 appears to play no role in
regulating apoptosis-induced by ABT-263 and YM-155 combi-
nation.
It has been reported that the activation of Raf-MEK-ERK-
survivin signaling pathway could protect endothelial cells
against gamma-radiation-induced apoptosis [41]. It is possible
that incubation of low dose ABT-263 could activate ERK-
survivin anti-apoptotic signal pathway to neutralize its Bcl-2
inhibition effects. In our study, we observed that low doses of
ABT-263 single treatment could result in increased phosphor-
ylation of ERK in the LH86 cells and survivin up-regulation,
suggesting low dose ABT-263 can activate ERK-survivin signal
pathway. These data may first provide an important and direct
explanation as to why low dose ABT-263 is unable to induce
apoptosis. More importantly, either using specific ERK
inhibitor PD98059 to pre-treat cells or using siRNA to knock
down ERK protein expression significantly sensitized sub-lethal
ABT-263-induced apoptosis in H C Cc e l l s ,s u g g e s t i n gt h a tE R K
anti-apoptotic signal pathway activation could render cells
resistant to this Bcl-2 inhibitor toxicity. These findings are in
agreement with previous reports that ERK-survivin signal
pathway can regulate chemotherapeutic reagents-induced ap-
optosis [25,26]. Finally, our results demonstrated normal human
hepatocytes are resistant to the combination of ABT-263 and
YM-155, of which the mechanism underlying remains to be
investigated.
Overall, the data from this study have led to the following
conclusions: low doses of ABT-263 alone could not induce
apoptosis in HCC cells. Survivin inhibition sensitized this bcl-2
inhibitor to induce apoptosis in HCC cells, but not in normal
human primary hepatocytes. ERK signal pathway activation may
be involved in the protection of cells against apoptosis exerted by
Bcl-2 inhibitor. Since ABT-263 and YM-155 have already shown
promising results in clinical trials in other types of cancers, the
current data may provide a basic clue for clinical trial of their
combination in HCC treatment.
Figure 7. ABT-263 has no apoptotic toxicity to normal human
hepatocytes. A. Freshly prepared normal human hepatocytes were
grown in 6-well plates. After two days later, cells were treated with
various conditions as indicated. Apoptosis were assessed through
Western blotting to detect activation of caspase 3 with specific
antibody. Cell lysates from hepatoblastoma cells (HB01) treated with a
combination of ABT-263 (1 mM) and YM-155 (1 mM) for up to 6 h were
set up as a positive control. b-actin was detected and served as an equal
protein loading control.
doi:10.1371/journal.pone.0021980.g007
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